The global prevalence of allergic illnesses is likely to fuel growth in the global allergy treatment market during the forecast period. The most prevalent allergic illnesses affecting children are asthma, allergic rhinitis, atopic dermatitis, and food allergies, and the incidence of these problems has increased in recent years. Regulatory agencies' frequent approval of new medications is projected to drive the global allergy treatment market over the forecast period. Because of the rising incidence of allergic disorders, there is a growing demand for safe and efficient therapy. People's lack of knowledge about allergy immunotherapy is projected to stymie the worldwide allergy treatment market's expansion. Despite a significant growth in the frequency of allergens in people, allergic disorders are still frequently underdiagnosed and underestimated due to a lack of knowledge in both developed and developing countries. The growing preference for biosimilars is projected to stifle expansion in the worldwide allergy treatment industry.
According to Coherent Market Insights, The global Allergy Treatment Market was valued at US$ 17,773.4 Mn in 2021 and is forecast to reach a value of US$ 27,347.4 Mn by 2028 at a CAGR of 6.4% between 2022 and 2028.
Market Leaders in the Allergy Treatment Industry:
1. AbbVie Inc. (Allergan)
AbbVie develops pharmaceuticals and medical devices. They provide products and services to therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology. The company was founded in 2013, headquartered in Illinois, U.S.
2. Allergy Therapeutics PLC
Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom. Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Acarovac Plus, Pollinex, and VLP Peanut.In October 2019, Allergan PLC announced the launch of three new over-the-counter (OTC) Refresh Relieva products. Refresh Relieva, Refresh Relieva PF (preservative-free) multidose, and Refresh Relieva for Contacts.
3. Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. In February 2021, Bausch + Lomb launched Alaway Preservative Free antihistamine eye drops in the United States, the first and only over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the U.S. Food and Drug Administration (FDA). In March 2021, Bausch Health Companies Inc. and Glenmark Pharmaceuticals entered into an exclusive licensing agreement for the commercialization of Glenmark's innovative nasal spray RYALTRIS under review by Health Canada. Bausch Health Companies Inc. is headquartered in Laval, Canada. Founded in